237 related articles for article (PubMed ID: 25562725)
21. Lack of impairment due to confirmed codeine use prior to a motor vehicle accident: role of pharmacogenomics.
Wu AH; Kearney T
J Forensic Leg Med; 2013 Nov; 20(8):1024-7. PubMed ID: 24237812
[TBL] [Abstract][Full Text] [Related]
22. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects.
Poulsen L; Brøsen K; Arendt-Nielsen L; Gram LF; Elbaek K; Sindrup SH
Eur J Clin Pharmacol; 1996; 51(3-4):289-95. PubMed ID: 9010701
[TBL] [Abstract][Full Text] [Related]
23. Pharmacogenetic determination of the effects of codeine and prediction of drug interactions.
Caraco Y; Sheller J; Wood AJ
J Pharmacol Exp Ther; 1996 Sep; 278(3):1165-74. PubMed ID: 8819499
[TBL] [Abstract][Full Text] [Related]
24. Functional phenotyping of the CYP2D6 probe drug codeine in the horse.
Gretler SR; Finno CJ; Kass PH; Knych HK
BMC Vet Res; 2021 Feb; 17(1):77. PubMed ID: 33581736
[TBL] [Abstract][Full Text] [Related]
25. CYP2D6 genotype and reduced codeine analgesic effect in real-world clinical practice.
Carranza-Leon D; Dickson AL; Gaedigk A; Stein CM; Chung CP
Pharmacogenomics J; 2021 Aug; 21(4):484-490. PubMed ID: 33750887
[TBL] [Abstract][Full Text] [Related]
26. Re: Apnea in a child after oral codeine: a genetic variant - an ultra-rapid metabolizer [corrected].
de Wildt SN; Koren G
Paediatr Anaesth; 2008 Mar; 18(3):273-4; author's reply 275-6. PubMed ID: 18230076
[No Abstract] [Full Text] [Related]
27. On the assessment of drug metabolism by assays of codeine and its main metabolites.
Haffen E; Paintaud G; Berard M; Masuyer C; Bechtel Y; Bechtel PR
Ther Drug Monit; 2000 Jun; 22(3):258-65. PubMed ID: 10850391
[TBL] [Abstract][Full Text] [Related]
28. The pharmacokinetics of codeine and its metabolites in Blacks with sickle cell disease.
Shord SS; Cavallari LH; Gao W; Jeong HY; Deyo K; Patel SR; Camp JR; Labott SM; Molokie RE
Eur J Clin Pharmacol; 2009 Jul; 65(7):651-8. PubMed ID: 19357842
[TBL] [Abstract][Full Text] [Related]
29. Pharmacogenomics of codeine, morphine, and morphine-6-glucuronide: model-based analysis of the influence of CYP2D6 activity, UGT2B7 activity, renal impairment, and CYP3A4 inhibition.
Eissing T; Lippert J; Willmann S
Mol Diagn Ther; 2012 Feb; 16(1):43-53. PubMed ID: 22352453
[TBL] [Abstract][Full Text] [Related]
30. Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation?
Lötsch J; Rohrbacher M; Schmidt H; Doehring A; Brockmöller J; Geisslinger G
Pain; 2009 Jul; 144(1-2):119-24. PubMed ID: 19395173
[TBL] [Abstract][Full Text] [Related]
31. CYP2D6 pharmacogenetic and oxycodone pharmacokinetic association study in pediatric surgical patients.
Balyan R; Mecoli M; Venkatasubramanian R; Chidambaran V; Kamos N; Clay S; Moore DL; Mavi J; Glover CD; Szmuk P; Vinks A; Sadhasivam S
Pharmacogenomics; 2017 Mar; 18(4):337-348. PubMed ID: 28244808
[TBL] [Abstract][Full Text] [Related]
32. Codeine-related deaths: The role of pharmacogenetics and drug interactions.
Lam J; Woodall KL; Solbeck P; Ross CJ; Carleton BC; Hayden MR; Koren G; Madadi P
Forensic Sci Int; 2014 Jun; 239():50-6. PubMed ID: 24747667
[TBL] [Abstract][Full Text] [Related]
33. Physiologically based pharmacokinetic modeling revealed minimal codeine intestinal metabolism in first-pass removal in rats.
Noh K; Chen S; Yang QJ; Pang KS
Biopharm Drug Dispos; 2017 Jan; 38(1):50-74. PubMed ID: 27925239
[TBL] [Abstract][Full Text] [Related]
34. Apnea in a child after oral codeine: a genetic variant - an ultra-rapid metabolizer.
Voronov P; Przybylo HJ; Jagannathan N
Paediatr Anaesth; 2007 Jul; 17(7):684-7. PubMed ID: 17564651
[TBL] [Abstract][Full Text] [Related]
35. Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease.
Gammal RS; Crews KR; Haidar CE; Hoffman JM; Baker DK; Barker PJ; Estepp JH; Pei D; Broeckel U; Wang W; Weiss MJ; Relling MV; Hankins J
Pediatrics; 2016 Jul; 138(1):. PubMed ID: 27335380
[TBL] [Abstract][Full Text] [Related]
36. Reviewing pharmacogenetics to advance precision medicine for opioids.
Magarbeh L; Gorbovskaya I; Le Foll B; Jhirad R; Müller DJ
Biomed Pharmacother; 2021 Oct; 142():112060. PubMed ID: 34523422
[TBL] [Abstract][Full Text] [Related]
37. Codeine: Time to Say "No".
Tobias JD; Green TP; Coté CJ; ;
Pediatrics; 2016 Oct; 138(4):. PubMed ID: 27647717
[TBL] [Abstract][Full Text] [Related]
38. Influence of Cytochrome P450, Family 2, Subfamily D, Polypeptide 6 (CYP2D6) polymorphisms on pain sensitivity and clinical response to weak opioid analgesics.
Zahari Z; Ismail R
Drug Metab Pharmacokinet; 2014; 29(1):29-43. PubMed ID: 23759977
[TBL] [Abstract][Full Text] [Related]
39. Pharmacogenomics: why standard codeine doses can have serious toxicities or no therapeutic effect.
Kelly PA
Oncol Nurs Forum; 2013 Jul; 40(4):322-4. PubMed ID: 23803265
[No Abstract] [Full Text] [Related]
40. Urinary excretion of codeine, ethylmorphine, and their metabolites: relation to the CYP2D6 activity.
Hedenmalm K; Sundgren M; Granberg K; Spigset O; Dahlqvist R
Ther Drug Monit; 1997 Dec; 19(6):643-9. PubMed ID: 9421105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
